5-HT<sub>2C</sub> Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29398112.
- Also identified by DOI 10.1016/j.cell.2018.01.001 and PMC identifier 6309861.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Drugs frequently require interactions with multiple targets-via a process known as polypharmacology-to achieve their therapeutic actions. Currently, drugs targeting several serotonin receptors, including the 5-HT<sub>2C</sub> receptor, are useful for treating obesity, drug abuse, and schizophrenia. The competing challenges of developing selective 5-HT<sub>2C</sub> receptor ligands or creating drugs with a defined polypharmacological profile, especially aimed at G protein-coupled receptors (GPCRs), remain extremely difficult. Here, we solved two structures of the 5-HT<sub>2C</sub> receptor in complex with the highly promiscuous agonist ergotamine and the 5-HT<sub>2A-C</sub> receptor-selective inverse agonist ritanserin at resolutions of 3.0 Å and 2.7 Å, respectively. We analyzed their respective binding poses to provide mechanistic insights into their receptor recognition and opposing pharmacological actions. This study investigates the structural basis of polypharmacology at canonical GPCRs and illustrates how understanding characteristic patterns of ligand-receptor interaction and activation may ultimately facilitate drug design at multiple GPCRs.
Medical subject headings
- Ergotamine
- Receptor, Serotonin, 5-HT2C
- Ritanserin
- Serotonin 5-HT2 Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists